- Atomoxetine (Strattera®)
- Citalopram (Celexa®)
- Coenzyme Q-10 - PREQUEL
- Creatine - PRECREST
- Ethyl-EPA (Miraxion)
- Memantine (Namenda®)
- Minocycline (Minocin®)
- Tetrabenazine (Nitoman®, Xenazine®)
Clinical Trial Background by Huntington Study Group (HSG)
Clinical Trial Background by NIH ClinicalTrials.gov
List of Clinical Trials by NIH ClinicalTrials.gov
Trial information at NIH ClincalTrials.gov
Trial Status: Completed.
FDA Phase: Phase 2 safety trial
Sponsors: Huntington's Study Group and NINDS
Trial Results: Of the dosages used in this trial, 1200 mg of CoQ-10 was better tolerated than the larger 2400 mg dose.
Trial Description: 90 participants who are positive for the HD gene but have no symptoms. Study duration will be 18 months during which the safety and tolerability of 1200 and 2400 mg dosing will be studied.
Outcome Measures: This is not a trial testing efficacy, however blood tests will be followed for oxidative injury biomarkers.
Locations: See ClinicalTrials.gov page for the trial.